| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(8 months ago) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
Qtern is owned by Astrazeneca Ab.
Qtern contains Dapagliflozin; Saxagliptin Hydrochloride.
Qtern has a total of 11 drug patents out of which 4 drug patents have expired.
Expired drug patents of Qtern are:
- US6936590
- US9198925
- US6414126
- USRE44186
Qtern was authorised for market use on 02 May, 2019.
Qtern is available in tablet;oral dosage forms.
Qtern can be used as method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin, treatment of type 2 diabetes mellitus.
Drug patent challenges can be filed against Qtern from 08 January, 2018.
The generics of Qtern are possible to be released after 16 December, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-175) | Apr 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| New Combination(NC) | Feb 27, 2020 |
| New Strength(NS) | May 02, 2022 |
| New Indication(I-804) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; Treatment of type 2 diabetes mellitus
Dosage: TABLET;ORAL
QTERN family patents
